Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Merit Medical Systems in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Merit Medical Systems’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:23 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000856982-26-000025
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Gross profit | 184,797 | 172,020 |
| Operating expenses: | ||
| Selling, general and administrative | 118,210 | 107,486 |
| Research and development | 22,609 | 22,478 |
| Contingent consideration (benefit) expense | (179) | 1,023 |
| Total operating expenses | 140,640 | 130,987 |
| Income from operations | 44,157 | 41,033 |
| Other income (expense): |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Merit Medical Systems's R&D?
- Merit Medical Systems (MMSI) reported R&D of $22.61M in Q1 2026.
- How has Merit Medical Systems's R&D changed year-over-year?
- Merit Medical Systems's R&D increased by 0.6% year-over-year, from $22.48M to $22.61M.
- What is the long-term trend for Merit Medical Systems's R&D?
- Over 4 years (2021 to 2025), Merit Medical Systems's R&D has grown at a 8.1% compound annual growth rate (CAGR), from $71.25M to $97.35M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Merit Medical Systems's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude